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Sporadic associations between inflammatory myopathies with vaccinations were described in the literature, raising the possible
trigger value of vaccines in the development of these autoimmune disorders. Here, we reported the clinical history of 3 patients
who developed polymyositis complicated by interstitial lung disease (2 cases) and dermatomyositis (1 case), after influenza A
(H1N1) vaccination.
1. Introduction
The safety of pandemic influenza A (H1N1) vaccine, given
alone or simultaneously with seasonal trivalent influenza
vaccine, has been demonstrated [1–5]. Vaccine-related
adverse events are generally mild, including pain at injection
site, fever, myalgias, and fatigue. Here, we described 3
patients, firstly referred to Infectious Disease Unit of our
university-based hospital and successively to our Rheuma-
tology Unit, because of recent-onset high fever, respiratory
symptoms, and marked muscle weakness. This clinical
picture followed the administration of pandemic A H1N1
(Focetria, Novartis) and seasonal trivalent (Vaxigrip, Sanofi
Pasteur MSD) influenza vaccines. No previous infections
before the vaccinations were reported. Patients’ clinicosero-
logical features are summarized in Table 1.
2. Case reports
2.1. Patient 1. In November 2009, this 59-year-old woman
developed high fever, cough, and dyspnea few days after
receiving influenza vaccines. Two weeks later, she was
hospitalized because of the rapid worsening of symptoms,
resistant to antibiotic therapy. Diffuse infiltrates in both
lungs and marked proximal muscle weakness were observed;
wide laboratory and radiological evaluations, including lung
high-resolution computed tomography (HRCT) and bron-
choalveolar lavage (BAL), excluded infectious or neoplastic
diseases. In January 2010, diagnosis of polymyositis (PM)
with diffuse organizing pneumonia was done on the basis
of clinicoserological and EMG alterations. Patient’s general
conditions and muscle involvement rapidly improved since
the first week of steroid treatment; however, considering
that a second lung HRCT revealed an evolution to diffuse
interstitial involvement, mycophenolate mofetil was added
at the fifth week of steroid treatment. To date, PM remains
slightly active (CK 150–200UI/mL), along with a fibromyal-
gic/depressive syndrome.
2.2. Patient 2. This 60-year-old male patient presented
a past history of recurrent episodes of cough, fever,
and arthromyalgias. In December 2009, one month after
influenza vaccines, he showed high fever, dyspnea, and
rapidly progressive proximal muscle weakness. At the
patient’s hospitalization, bibasilar lung infiltrates were
observed, followed by rapid increase of creatinine kinase.
Possible infectious or neoplastic diseases were excluded by
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Table 1
Patient 1 Patient 2 Patient 3
Sex/age (y)/race/smoke F/59/Afro-American/— M/60/African/— F/71/Caucasian/—
Symptoms
Fever, cough, dyspnea, diffuse
lung infiltrates, proximal muscle
weakness
Fever, cough, dyspnea, basilar
lung infiltrates, proximal muscle
weakness
Proximal muscle weakness,
severe dysphagia, periungueal
erythema, periocular bullous
heliotropic lesions
Onset after vaccination 5 days 30 days 7 days
CK (nv < 170U/L) 1-2-3 2,685-569-98 6,589-1,700-752 1,325-67-20
EMG myogenic
alterations
+ + +
Autoimmunity
ANA 1 : 640 (speckled); ENA-
ASMA-; AMA-; ANCA-
ANA 1 : 320 (speckled); ENA+
(Jo1); ASMA+ 1 : 160; AMA-;
ANCA-
ANA 1 : 320 (speckled); ENA+
(Ro/SSA); AMA-; ASMA-;
ANCA-
Treatment
6-MP 1mg/Kg/day → slowly
tapered to 8mg/day;
Mycophenolate mofetil 2 g/day
from February 2010
Predn. 1.5mg/Kg/day → slowly
tapered to 25mg/day
Methotrexate 20mg/week; IVIG
1mg/kg monthly (February–May
2010); start of Cyclosporine
200mg/day from September
2010
6-MP 1mg/Kg/day → slowly
tapered to 16mg/day; IVIG
1mg/kg monthly
(March–August 2010)
Outcome Remission Partially improved
Died in November 2010
(Epstein-Barr virus reactivation)
CK: creatinine kinase (1: at baseline; 2: 1 month after therapy beginning; 3: at the end of followup, in December 2010); EMG: electromyography; ANA:
antinuclear antibodies; anti-ENA: antiextractable nuclear antigen antibodies; ASMA: antismooth muscle antibodies; AMA: antimitochondrial antibodies;
ANCA: antineutrophil cytoplasmic antibodies; 6-MP: 6-methylprednisolone, Predn: prednisone.
means of instrumental investigations, such as HRCT and
BAL fluid examination; therefore, diagnosis of PM with
basilar organizing pneumonia was done. Since the first 2
weeks of steroid treatment, the patient showed a rapid
improvement of both muscle and lung involvements. Inter-
estingly, patient 2 showed serum anti-ENA-Jo1 antibody,
a typical immunological marker of PM complicated by
interstitial lung disease [6]. Up to date, PM is well controlled
with ongoing therapy; a fibromyalgic syndrome remains as a
sequel.
2.3. Patient 3. In December 2009, this 71-year-old female
patient presented proximal muscle weakness, severe dys-
phagia, periungueal erythema, and periocular bullous
heliotropic lesions, just 7 days after the influenza vacci-
nations. The typical electromyographic alterations and the
straight raise of CK confirmed the diagnosis of polyder-
matomyositis (DM). The patient started steroid treatment
at dosage of 1mg/kg/day, slowly tapered in the following
period, along with monthly immunoglobulin’s infusions
until August 2010. In November 2010, despite the good
response to therapy of myositis, the patient presented
an abrupt deterioration of dermatitis, with appearance of
generalized erythroderma; thus, steroid dosage was raised
again to 1mg/kg/day. After about 40 days, the patient died
for an Epstein-Barr-related acute pneumonia.
3. Discussion
We presented 3 patients with inflammatory myopathies,
associated with interstitial lung disease in 2 cases, following
the vaccinations with H1N1 plus the seasonal trivalent
influenza. Interestingly, 2/3 cases are Italian citizens with the
genetic origin in sub-Saharan Western Africa; this finding is
difficult to entirely explain, but it is consistent with known
epidemiological data, which evidenced that inflammatory
myositis is more common in Afro-Americans [7].
In the literature, just one case of dermatomyositis after
the influenza vaccine was described by Jani et al. [8]. These
authors reported the clinical history of a 68-year-old woman
developing myositis with typical heliotrope discoloration
over eyelid two weeks after the vaccination; the treatment
with oral high-dose prednisolone and azathioprine was effec-
tive. Other sporadic case reports suggested the possible asso-
ciation between myopathies with vaccination for hepatitis B
virus, mycobacterium tuberculosis, tetanus, smallpox, polio,
diphtheria, and diphtheria-pertussis-tetanus [9]. Indeed,
inflammatory myopathies are recognized to be triggered also
by viral infections in predisposed individuals [9].
Recent studies on large series of individuals pointed out
the safety of the 2009 pandemic influenza A H1N1 vaccine
[4, 5]. However, possible cases of inflammatory myopathies
triggered by this vaccination might have not been recorded
in these studies; in fact, (i) clinical signs might be developed
after few weeks from vaccines; (ii) possibly, the diagnosis of
PM/DM may be formulated long time later or overlooked
entirely. Therefore, it is supposable that the actual incidence
of autoimmune disorders after influenza vaccination can
be underestimated in general clinical practice. On the
other hand, we cannot definitely exclude that the systemic
manifestations following influenza vaccination in our three
patients may be coincidental; however, it is supposable that
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vaccine-related viral antigens and/or adjuvants might play
a triggering role responsible for the observed autoimmune
complications, possibly in genetically predisposed subjects.
This hypothesis is in keeping with numerous clinical obser-
vations suggesting a possible link between myopathies and
infectious triggering agents [8–10].
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